Replies to post #13227 on Inovio Pharmaceuticals Inc (INO)

[Ubertino]

Roche and Inovio Pharmaceuticals partner on Inovio's prostate cancer and hepatitis B immunotherapy products

Basel, Switzerland and Blue Bell, PA, USA – 10 September 2013

Roche and Inovio Pharmaceuticals partner on Inovio’s prostate cancer and hepatitis B immunotherapy products

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio’s highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B. The licensed compounds are currently in preclinical development and have generated robust T-cell responses in animal models.
....
Roche is the world’s largest biotech company

http://www.roche.com/partnering/partnering_media_and_news/partnering_news-2013-09-10.htm